Most recent guideline publication:
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for NAT2 and Hydralazine Therapy (September 2025)
Updates since publication:
No updates on dosing recommendations since publication.
Tables provided in the main manuscript of the guideline:
| Table 1. Assignment of predicted NAT2 phenotype based on genotype |
| Table 2. Hydralazine oral dosing recommendations based on NAT2 phenotype in adults with resistant hypertension |
Supplement to: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for NAT2 and Hydralazine Therapy (September 2025)
Tables and figures provided in the guideline publication supplement or referenced in the guidelinea:
| Supplemental Table S1. Evidence linking NAT2 genotype to hydralazine phenotype |
| Figure S1. Hepatic metabolism of hydralazine |
| NAT2 allele definition table |
| NAT2 allele functionality table |
| NAT2 frequency table (in progress) |
| NAT2 diplotype-phenotype table |
| NAT2 gene resource mappings |
| Drug resource mapping Hydralazine |
| Clinical decision support:b Implementation workflow NAT2 consult Hydralazine pre- and post-test alerts and flow chart |
aSome of the tables included in the guideline may have been updated on-line, particularly to reflect newly described or newly characterized alleles. These include the gene-specific information tables https://www.clinpgx.org/page/nat2RefMaterials that support CPIC guidelines by providing information regarding star (*) allele definitions, allele function, allele frequency by major ethnic groups, translations of diplotype to phenotype, and gene resource mappings.
bThese resources support the adoption of CPIC guidelines into the electronic health record with clinical decision support and provide information that clinical implementers find helpful.